Products
Bempikibart Biosimilar Monoclonal Antibody (IL-7Rα) for Research
Cat No.: GMP-Bios-INN-1098
Anti-IL7R/CD127 therapeutic antibody (Pre-made Bempikibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Bempikibart (development code ADX-914) is a monoclonal antibody targeting IL-7 receptor alpha (IL7R). It is developed by Q32 Bio Inc. for atopic dermatitis. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1098-1mg | 1mg | 3090 |
| GMP-Bios-INN-1098-10mg | 10mg | |
| GMP-Bios-INN-1098-100mg | 100mg | |
| GMP-Bios-INN-1098-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Bempikibart biosimilar, Whole mAb, Anti-IL7R/CD127 Antibody: Anti-IL-7Ra/CD127/IL7R/Interleukin-7 receptor subunit alpha therapeutic antibody |
| INN Name | Bempikibart |
| Target | IL7R/CD127 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Q32 Bio Inc. |
| Conditions Approved | na |
| Conditions Active | Atopic dermatitis |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
